KOSPIBiotech & Pharma0126Z0

Samsung Epis Holdings

₩367,000▲ 1.38%2026-11-18 close
Market Cap
₩9.1T
Turnover
₩15.1B
Volume
40K
Shares out.
24.9M
PER
—
PBR
1.4×
EPS
—
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q1–2025Q4) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Biosimilar cash flow tests the shift to new drugs

Samsung Epis Holdings is using biosimilar profits from its subsidiary to widen its new-drug pipeline, and its Q3 2026 operating profit of KRW 105.1 billion rebounded while revenue fell short of estimates.

  1. 1

    Q3 2026 revenue of KRW 441.9 billion (up 12.8% from Q2) and operating profit of KRW 105.1 billion (up 78.9%) show a quarterly rebound.

  2. 2

    Q3 operating profit beat the KRW 63.9 billion consensus compiled by Epic AI, while revenue came in 8.0% below the KRW 480.1 billion consensus.

  3. 3

    Biosimilar products accounted for 94.3% of first-half 2026 revenue, so the earnings base remains concentrated in a single business.

  4. 4

    The 2025 disclosed results show an operating loss of KRW 63.6 billion and an operating margin of -25.3%, while all three quarters of 2026 recorded operating profit.

  5. 5

    In new drugs, the ADC candidate SBE303 received clinical phase 1 approvals in Korea and the US, but the timing of monetizing new drugs and platforms has not been specified.

02

Business structure

Samsung Epis Holdings is a bio investment holding company established on November 3, 2025 through the spin-off of Samsung Biologics. Its 100%-owned subsidiary Samsung Bioepis commercializes biosimilars, while EPIS NexLab, set up in November 2025, develops technology platforms.

Samsung Bioepis has received approvals for 10 biosimilars covering 11 products and sells them in more than 40 countries. Among these, global sales expansion of SB12 (eculizumab), a Soliris biosimilar, and SB17 (ustekinumab), a Stelara biosimilar, was cited as a driver of the subsidiary's Q3 2026 results.

The business structure is concentrated in biosimilars. Biosimilar products and related revenue accounted for KRW 797.9 billion, or 94.3%, of first-half 2026 revenue of KRW 845.8 billion.

In Europe the company is expanding direct sales, and in the US it sells under a private-label system, and it has signed a partnership with Sandoz on follow-on biosimilar development and sales. Competition is intensifying, with new entrants and pressure on prices.

The company targets a portfolio of 20 biosimilars by 2030 and is developing biosimilars of seven blockbuster drugs including Keytruda and Dupixent. The new-drug business is at an early stage, centered on the ADC candidate SBE303, and new-business investment stands at about KRW 50.9 billion.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3———
2025Q4———
2026Q1₩453.9B₩90.5B19.9%
2026Q2₩391.9B₩58.7B15.0%
2026Q3₩441.9B₩105.1B23.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2025₩251.7B-₩63.6B₩85.3B−25.3%1.4%30.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On the disclosed basis, 2025 revenue was KRW 251.7 billion and the operating loss was KRW 63.6 billion, an operating margin of -25.3%.

In the same year, net income attributable to controlling shareholders was KRW 85.3 billion and net income including non-controlling interests was also KRW 85.3 billion, so the operating loss and net profit moved in different directions.

Total equity at the end of 2025 was KRW 5.91 trillion and total liabilities were KRW 1.81 trillion, giving a debt ratio of 30.6%. Operating cash flow in 2025 was -KRW 103.7 billion.

Because the company was established in November 2025, the 2025 figures cover a partial post-establishment period and limit direct comparison with 2026. In Q1 2026, revenue was KRW 453.9 billion, operating profit KRW 90.5 billion and net income attributable to controlling shareholders KRW 99.5 billion.

In Q2, revenue fell to KRW 391.9 billion (down 13.7% from the prior quarter), operating profit to KRW 58.7 billion (down 35.1%) and controlling-shareholder net income to KRW 85.8 billion (down 13.7%).

In Q3, revenue rebounded to KRW 441.9 billion (up 12.8%), operating profit to KRW 105.1 billion (up 78.9%) and controlling-shareholder net income to KRW 96.3 billion (up 12.2%). Q3 operating profit exceeded the KRW 63.9 billion consensus compiled by Epic AI, while revenue was 8.0% below the KRW 480.1 billion consensus.

Cumulative January to September 2026 revenue reported on October 28, 2026 was KRW 1.29 trillion and operating profit was KRW 254.4 billion, a cumulative operating margin of 19.7%.

At subsidiary Samsung Bioepis, Q3 revenue was KRW 442.2 billion and operating profit KRW 132.6 billion, and excluding milestone income, product-sales operating profit rose 21.3% to KRW 106.9 billion.

Consolidated results at the holding level differ from the subsidiary's because of non-cash purchase accounting adjustments, including amortization of development costs from purchase price allocation.

05

Industry analysis

The biosimilar market becomes more competitive once the original drugs lose exclusivity, as multiple copy products compete for the same therapies. The company is responding by expanding direct sales in Europe and selling under private labels in the US.

Industry observers note that even as product counts rise, new entrants and price-cut pressure make it uncertain whether past profitability levels will hold. On policy, the company cited international trade changes and drug price reductions as reasons for the spin-off of Samsung Biologics.

Its commercialization experience with 11 products in more than 40 countries is presented as a competitive strength. In new drugs, antibody-drug conjugates are described as an area drawing attention as next-generation cancer therapies.

With artificial intelligence adoption accelerating across the industry, the company is pursuing AI-based antibody design collaborations. The structure of moving cash generated from biosimilars into new-drug research is described as the company's point of difference.

Clinical success rates for new drugs are uncertain at each stage, which makes that business different in character from biosimilars.

06

Outlook

The company's stated 2026 targets are revenue growth of 10% or more versus the prior year and an operating margin of 20% or more. Reaching the revenue target requires at least KRW 1.84 trillion, and cumulative January to September revenue of KRW 1.29 trillion equals 70.0% of that level.

The cumulative operating margin of 19.7% is close to the 20% threshold. The prior-year base of KRW 1.67 trillion cited for the target matches the 2025 revenue of subsidiary Samsung Bioepis, which differs in scope from the holding company's 2025 revenue in the disclosed table.

In new drugs, the ADC candidate SBE303 received FDA fast-track designation, and the follow-on candidate SBE313 is at the preclinical stage. The company has said it will add at least one late-stage new-drug candidate each year.

In biosimilars, it filed for FDA marketing approval of SB27, a Keytruda biosimilar, in October 2026. Partnerships since early 2026 include a follow-on pipeline deal with Sandoz and a joint research and licensing agreement with Jiten Bio on an obesity treatment.

The company targets a 20-product biosimilar portfolio by 2030. In AI-based new-drug work, it aims to identify new candidates capable of entering clinical phase 1 by the end of 2027.

The timing of monetization for the KRW 50.9 billion in new-business investment, including convertible bond investments, has not been specified.

07

Valuation

PER
—
PBR
1.4×
ROE
1.4%
EPS
—
BPS
₩248,714
Dividend per share
₩0

Price-to-book measures the share price relative to net assets, and the company's market capitalization sits above its book equity of KRW 5.91 trillion at the end of 2025. A premium to net assets can be read as the market pricing in earnings power or pipeline value beyond book assets.

The shift from a 2025 operating loss to cumulative January to September 2026 operating profit of KRW 254.4 billion is one background for this premium. However, because the 2025 figures cover a partial post-establishment period, a continuous growth rate in profit cannot be stated with confidence.

The dividend yield is low, so shareholder returns depend more on share price movement than on dividends. The KRW 50.9 billion of new investment and the uncertain timing of new-drug monetization remain items to track against current profit levels.

A comparison with sector averages requires contemporaneous multiples of listed peers, and this report limits the comparison to the facts.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Q3 profit rebound and beat on consensus

Q3 2026 operating profit of KRW 105.1 billion exceeded the Q1 figure of KRW 90.5 billion and the Q2 figure of KRW 58.7 billion. It was also above the KRW 63.9 billion consensus compiled by Epic AI. The cumulative January to September operating margin of 19.7% is close to the company's 20% or higher target.

Product-sales profit improvement at the subsidiary

At subsidiary Samsung Bioepis, Q3 2026 operating profit excluding milestone income rose 21.3% to KRW 106.9 billion. The company attributed this to expanded global sales of SB12 (eculizumab) and SB17 (ustekinumab).

That product-sales profit grew after excluding one-time milestone income is read as a strength in earnings quality.

Entry into the new-drug pipeline

The ADC candidate SBE303 received FDA fast-track designation and clinical phase 1 approvals in Korea and the US. The company has said it plans to add at least one late-stage candidate each year. It has also said that cash flow from biosimilars can cover its new-drug investment.

09

Bear factors

Concentration of earnings in biosimilars

Biosimilar products accounted for 94.3% of first-half 2026 revenue. With dependence on a single business this high, price cuts or intensifying competition feed directly into results. The timing of monetization for new drugs and platforms has not been specified.

Challenge in reaching the revenue target

Cumulative January to September revenue of KRW 1.29 trillion equals 70.0% of the KRW 1.84 trillion needed to reach the 2026 revenue target. Q3 revenue came in 8.0% below the Epic AI consensus. Some market commentary suggests the annual revenue target may be difficult to reach.

New-drug investment burden and quarterly volatility

Since the spin-off, new-business investment has reached about KRW 50.9 billion. Q2 operating profit fell 35.1% from Q1 to KRW 58.7 billion. Because quarterly profit has fluctuated this much, whether the Q3 recovery continues requires further quarterly data.

10

Risk factors

Policy and drug pricing risk

Samsung Biologics cited international trade changes and drug price reductions as external policy uncertainties behind the spin-off. Biosimilar prices are directly affected by drug pricing policy. If policy changes reduce selling prices and profitability, the effect flows directly into consolidated results.

Competition and pricing pressure

As new entrants and price-cut pressure grow, it is uncertain whether a larger product count will deliver the same profitability as before. Industry commentary holds that securing product-level profitability now matters as much as gaining market share. If follow-on products contribute less profit than expected, growth in earnings could be limited.

Uncertainty in clinical development and monetization

Success at each clinical stage is uncertain for new-drug candidates, and SBE313 remains at the preclinical stage. The timing of monetization for technology platforms and new drugs has not been specified.

Given the 2025 operating loss and operating cash flow of -KRW 103.7 billion, new-drug investment costs could weigh on short-term profit.

11

What to watch next

  1. Early 2027

    The Q4 and full-year 2026 preliminary results will show whether revenue met the target of 10% or more growth and whether the operating margin held at 20% or above.

  2. End of March 2027

    The deadline for the 2026 annual report will show the full-year sums of quarterly results, the composition of non-operating items, and changes in operating cash flow.

  3. 2027 (timing not yet set)

    The FDA review outcome for SB27, a Keytruda biosimilar filed in October 2026, will indicate the pace of commercialization in the biosimilar pipeline.

  4. End of 2027

    Whether the new-drug candidates identified through AI collaboration enter clinical phase 1 will show whether the new-drug business moves into actual trials.

  5. 2030

    Whether the 20-product biosimilar portfolio target is reached will be checked, and the key question is whether a larger product count translates into product-level profitability.

12

Overall view

Samsung Epis Holdings is widening its scope into new drugs on the back of profits from its biosimilar subsidiary, Samsung Bioepis. Q3 2026 operating profit of KRW 105.1 billion reflected a quarterly recovery and exceeded analyst estimates.

Revenue, however, fell 8.0% short of consensus, and cumulative January to September revenue equals 70.0% of the level needed to reach the 2026 target. Earnings remain concentrated in biosimilars, which made up 94.3% of first-half 2026 revenue, so pricing and competition weigh heavily.

In new drugs, SBE303 has cleared clinical phase 1 approvals and received FDA fast-track designation, but the timing of monetization has not been set. The 2025 results show an operating loss and negative operating cash flow, and quarterly operating profit in 2026 has moved up and down.

The next checkpoints are whether the Q4 and full-year 2026 preliminary results meet the revenue target, the non-operating items and cash flow in the 2026 annual report, the FDA review of SB27, and whether new-drug candidates enter the clinic.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. digitaltoday.co.kr
  2. hankyung.com
  3. econovill.com
  4. medicopharma.co.kr
  5. insightkorea.co.kr
  6. inthenews.co.kr
  7. m.news.nate.com
  8. mydaily.co.kr
  9. view.asiae.co.kr
  10. pharmnews.com
  11. samsungbiologics.com
  12. sedaily.com
  13. sisajournal-e.com
  14. ebn.co.kr
  15. goodkyung.com
  16. etoday.co.kr
  17. hitnews.co.kr
  18. kmib.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis